We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns of Raptiva Risks, EMEA Considers Suspension
FDA Warns of Raptiva Risks, EMEA Considers Suspension
February 20, 2009
The FDA issued a public health advisory for Genentech’s psoriasis drug Raptiva and the European Medicines Agency (EMEA) has recommended suspending its marketing authorization based on reports of cases of progressive multifocal leukoencephalopathy (PML) in patients taking the drug.